BACKGROUND: We studied prevalence and correlates of latent tuberculosis infection (LTBI) among injection drug users (IDUs) in Tijuana, Mexico, where tuberculosis (TB) is endemic. METHODS: IDUs aged > or =18 years were recruited via respondent-driven sampling (RDS) and underwent standardized interviews, human immunodeficiency virus (HIV) antibody testing and LTBI screening using Quanti-FERON((R))-TB Gold In-Tube, a whole-blood interferon-gamma release assay (IGRA). LTBI prevalence was estimated and correlates were identified using RDS-weighted logistic regression. RESULTS: Of 1020 IDUs, 681 (67%) tested IGRA-positive and 44 (4%) tested HIV-positive. Mean age was 37 years, 88% were male and 98% were Mexican-born. IGRA positivity was associated with recruitment nearest the US border (aOR 1.64, 95%CI 1.09-2.48), increasing years of injection (aOR 1.20/5 years, 95%CI 1.07-1.34), and years lived in Tijuana (aOR 1.10/5 years, 95%CI 1.03-1.18). Speaking some English (aOR 0.38, 95%CI 0.25-0.57) and injecting most often at home in the past 6 months (aOR 0.68, 95%CI 0.45-0.99) were inversely associated with IGRA positivity. DISCUSSION: Increased LTBI prevalence among IDUs in Tijuana appears to be associated with greater drug involvement. Given the high risk for HIV infection among Tijuana's IDUs, interventions are urgently needed to prevent HIV infection and treat LTBI among IDUs before these epidemics collide.
BACKGROUND: We studied prevalence and correlates of latent tuberculosis infection (LTBI) among injection drug users (IDUs) in Tijuana, Mexico, where tuberculosis (TB) is endemic. METHODS: IDUs aged > or =18 years were recruited via respondent-driven sampling (RDS) and underwent standardized interviews, human immunodeficiency virus (HIV) antibody testing and LTBI screening using Quanti-FERON((R))-TB Gold In-Tube, a whole-blood interferon-gamma release assay (IGRA). LTBI prevalence was estimated and correlates were identified using RDS-weighted logistic regression. RESULTS: Of 1020 IDUs, 681 (67%) tested IGRA-positive and 44 (4%) tested HIV-positive. Mean age was 37 years, 88% were male and 98% were Mexican-born. IGRA positivity was associated with recruitment nearest the US border (aOR 1.64, 95%CI 1.09-2.48), increasing years of injection (aOR 1.20/5 years, 95%CI 1.07-1.34), and years lived in Tijuana (aOR 1.10/5 years, 95%CI 1.03-1.18). Speaking some English (aOR 0.38, 95%CI 0.25-0.57) and injecting most often at home in the past 6 months (aOR 0.68, 95%CI 0.45-0.99) were inversely associated with IGRA positivity. DISCUSSION: Increased LTBI prevalence among IDUs in Tijuana appears to be associated with greater drug involvement. Given the high risk for HIV infection among Tijuana's IDUs, interventions are urgently needed to prevent HIV infection and treat LTBI among IDUs before these epidemics collide.
Authors: Steffanie A Strathdee; Morgan M Philbin; Shirley J Semple; Minya Pu; Prisci Orozovich; Gustavo Martinez; Remedios Lozada; Miguel Fraga; Adela de la Torre; Hugo Staines; Carlos Magis-Rodríguez; Thomas L Patterson Journal: Drug Alcohol Depend Date: 2007-08-21 Impact factor: 4.492
Authors: Emily Faye White; Richard S Garfein; Kimberly C Brouwer; Remedios Lozada; Rebeca Ramos; Michelle Firestone-Cruz; Saida G Pérez; Carlos Magis-Rodríguez; Carlos J Conde-Glez; Steffanie A Strathdee Journal: Salud Publica Mex Date: 2007 May-Jun
Authors: Morgan M Philbin; Andrea Mantsios; Remedios Lozada; Patricia Case; Robin A Pollini; Jorge Alvelais; Carl A Latkin; Carlos Magis-Rodriguez; Steffanie A Strathdee Journal: Int J Drug Policy Date: 2008-10-28
Authors: Steffanie A Strathdee; Remedios Lozada; Robin A Pollini; Kimberly C Brouwer; Andrea Mantsios; Daniela A Abramovitz; Tim Rhodes; Carl A Latkin; Oralia Loza; Jorge Alvelais; Carlos Magis-Rodriguez; Thomas L Patterson Journal: J Acquir Immune Defic Syndr Date: 2008-03-01 Impact factor: 3.731
Authors: Anandharaman Veerapathran; Rajnish Joshi; Kalyan Goswami; Sandeep Dogra; Erica E M Moodie; M V R Reddy; Shriprakash Kalantri; Kevin Schwartzman; Marcel A Behr; Dick Menzies; Madhukar Pai Journal: PLoS One Date: 2008-03-26 Impact factor: 3.240
Authors: S S Shin; R Laniado-Laborin; P G Moreno; T E Novotny; S A Strathdee; R S Garfein Journal: Int J Tuberc Lung Dis Date: 2013-11 Impact factor: 2.373
Authors: Angela R Bazzi; Jennifer L Syvertsen; María Luisa Rolón; Gustavo Martinez; Gudelia Rangel; Alicia Vera; Hortensia Amaro; Monica D Ulibarri; Daniel O Hernandez; Steffanie A Strathdee Journal: J Subst Abuse Treat Date: 2015-09-21
Authors: Adithya Cattamanchi; Rachel Smith; Karen R Steingart; John Z Metcalfe; Anand Date; Courtney Coleman; Barbara J Marston; Laurence Huang; Philip C Hopewell; Madhukar Pai Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Karla D Wagner; Robin A Pollini; Thomas L Patterson; Remedios Lozada; Victoria D Ojeda; Kimberly C Brouwer; Alicia Vera; Tyson A Volkmann; Steffanie A Strathdee Journal: Drug Alcohol Depend Date: 2011-01-15 Impact factor: 4.492
Authors: Richard S Garfein; Rafael Laniado-Laborin; Timothy C Rodwell; Remedios Lozada; Robert Deiss; Jose Luis Burgos; Jazmine Cuevas-Mota; Paris Cerecer; Kathleen Moser; Maria Luisa Volker; Steffanie A Strathdee Journal: Emerg Infect Dis Date: 2010-05 Impact factor: 6.883
Authors: R F Armenta; K M Collins; S A Strathdee; M A Bulterys; F Munoz; J Cuevas-Mota; P Chiles; R S Garfein Journal: Int J Tuberc Lung Dis Date: 2017-04-01 Impact factor: 2.373
Authors: Robert Deiss; Richard S Garfein; Remedios Lozada; Jose Luis Burgos; Kimberly C Brouwer; Kathleen S Moser; Maria Luisa Zuniga; Timothy C Rodwell; Victoria D Ojeda; Steffanie A Strathdee Journal: Am J Public Health Date: 2009-06-18 Impact factor: 9.308